Previous 10 |
Prelude Therapeutics (PRLD): Q3 GAAP EPS of -$5.25.Cash and cash equivalents of $234.8M.Press Release. For further details see: Prelude Therapeutics reports Q3 results
- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 -...
Gainers: Scholar Rock Holding (SRRK) +80%, Exact Sciences (EXAS) +18%, CHF Solutions (CHFS) +17%, CASI Pharmaceuticals (CASI) +13%, Prelude Therapeutics (PRLD) +8%.Losers: Catabasis Pharmaceuticals (CATB) -68%, Galera Therapeutics (GRTX)&...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe earnings season heats up next week, with high-fliers Netflix (NASDAQ:NFLX), Tesla (NASDAQ:TSLA) and Chipotle (NYSE:CM...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Tracking insider purchases is an overlooked but very informative strategy. It can provide undervalued stocks in the market and can make assumptions for future market returns. September's number of insider purchases was close to the historical average, indicating that insiders are not ...
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
Prelude Therapeutics Incorporated Website:
2024-07-27 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 07:00:07 ET Peter Lawson from Barclays issued a price target of $3.00 for PRLD on 2024-06-20 05:33:00. The adjusted price target was set to $3.00. At the time of the announcement, PRLD was trading at $3.87. The overall price target consensus is at $10.67 with ...
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2...